Our Advancing Precision Oncology Podcast Series engages with thought leaders and experts on expanding patient access to biomarkers and advanced testing capabilities. Improving health outcomes for cancer patients increasingly depends on access to biomarker testing. Rapid advancements in biomarker discovery and testing capabilities are at a tipping point that will significantly impact the development of new precision oncology therapies in the pipeline.
In this three-part series, we explore the role of biomarkers in advancing precision oncology and improving health outcomes for cancer patients. Join us as we delve into the rapidly expanding testing capabilities, the benefits of integrating multi-data sources, and the challenges and opportunities in the changing landscape.
Advancing precision oncology: Expanding patient access to biomarkers and testing capabilities, Part 1
In this first episode, join our clinical development and market access experts who discuss the role of biomarker research, discovery, and patient access in advancing precision oncology to date. Biomarkers have been central to improving patient outcomes and guiding treatment guidelines in lung, breast, and blood cancers. With that backdrop, our experts discuss the role of large-scale data sets and real-world evidence in furthering precision oncology research and improving patient outcomes in more types of cancer.
Advancing precision oncology: Expanding patient access to biomarkers and testing capabilities, Part 2
In this second episode on advancing precision oncology through patient access to biomarkers and testing, the discussion focuses on the benefits of integrating multi-omic data in precision oncology and how it can enhance treatment selection. Our experts discuss the importance of looking beyond genomics and considering other omics, such as immunomics and metabolomics, to gain a better understanding of the tumor and the patient's immune system and physiology.
The vision is to integrate all these diverse types of data to improve the ability to provide personalized treatment to patients. Our experts discuss the challenges of implementing expanded testing capabilities, including issues related to consent, data security, validation of tests, and the integration of these capabilities into standard clinical practice. They explore the role of large-scale data sets and real-world evidence in furthering precision oncology research and improving treatment options for cancer patients.
Join our thought leaders and subject matter experts on expanding patient access to biomarkers to advance precision oncology and improve health outcomes for more cancer patients.
Advancing precision oncology: Expanding patient access to biomarkers and testing capabilities, Part 3
In this third episode on advancing precision oncology, we continue discussing the role of expanding patient access to biomarkers and evolving testing capabilities. Our precision oncology experts delve into the challenges and opportunities that lie ahead in the rapidly changing landscape. They explore advancements in data, machine learning, and testing capabilities on the horizon. They also discuss the roles of payers and healthcare providers in ensuring patient access to these advancements.
- Dr. Gwyn Bebb, Senior Vice President and Global Therapeutic Head of Oncology
- Wyatt Gotbetter, Senior Vice President Worldwide, Access Consulting
Join our thought leaders and subject matter experts on expanding patient access to biomarkers to advance precision oncology and improve health outcomes for more cancer patients.
Contributing Expert
